Bristol-Myers Squibb and Exelixis are eying potential approval of a combination therapy for renal cell carcinoma following results from a late-stage study that showed a combination of Opdivo and Cabometyx met the primary endpoint of progression-free survival.
AstraZeneca and Merck announced that the Phase III GY004 trial of cediranib in combination with Lynparza compared to platinum-based chemotherapy in platinum-sensitive relapsed ovarian cancer failed to meet the primary endpoint.
A cheaper HIV prevention pill is going on sale in the United States, but experts say the price drop will not help as many people if doctors instead prescribe a newer, more expensive brand-name drug.
The U.S. Food and Drug Administration approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly’s Trijardy XR for lowering blood sugar in adults with type 2 diabetes.
BeiGene Ltd.’s cancer therapy combination for treating lung cancer in previously untreated patients met the main goal in a late-stage study.
Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s combination therapy to treat smoker’s lung.
GlaxoSmithKline Plc’s two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage trial.
Array BioPharma announced positive results from the Phase III BEACON CRC trial evaluating a triple combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovia (binimetinib), and the anti-EGFR antibody Erbitux (cetuximab) in patients with advanced BRAFV600E-mutant metastatic colorectal cancer after one or two lines of therapy.
Shares of Karyopharm Therapeutics skyrocketed more than 36 percent after the U.S. Food and Drug Administration approved the Newton, Mass.-based company’s Xpovio for treating multiple myeloma.
